An integrated reverse vaccinology strategy is used to identify conserved immunogenic regions from the Envelope protein and NS5 protein, and construct a multi-epitope vaccine for Usutu virus, predicting enhanced humoral and cellular immune-response patterns following repeated antigen administration.
Abstract
Usutu virus is an emerging mosquito-borne flavivirus with an expanding geographic distribution and increasing public health relevance, yet no licensed vaccine is currently available. This study used an integrated reverse vaccinology strategy to identify conserved immunogenic regions from the Envelope protein and NS5 protein, and construct a multi-epitope vaccine. Following sequential computational screening, the retained T-cell and B-cell epitopes satisfied the predefined selection criteria, while selected T-cell epitopes achieved an estimated 96.41% global population coverage. The final vaccine consisted of 240 amino acids and incorporated an adjuvant together with peptide linkers. Computational characterization indicated favorable physicochemical features and a refined three-dimensional model with improved stereochemical characteristics. Receptor-binding analyses predicted favorable interactions with TLR2 and TLR4, producing weighted docking scores of −1326.1 and −1230.2, respectively. Molecular dynamics simulation further characterized the temporal behavior of the vaccine–TLR2 complex, while MM-GBSA analysis yielded an estimated binding energy of −74.78 kcal/mol. C-ImmSim predicted enhanced humoral and cellular immune-response patterns following repeated antigen administration, including increased simulated antibody levels and changes in immune-cell populations. All findings in this study are based on in silico analyses and represent computational predictions rather than experimentally confirmed results. Further experimental validation is required to verify the predicted properties, immunogenicity, and protective potential of the proposed vaccine candidate.
Staphylococcus lugdunensis has emerged as an increasingly important opportunistic pathogen associated with invasive infections and rising antimicrobial resistance, creating a need for new preventive approaches. In this study, a reverse-vaccinology strategy integrated with immunoinformatics analyses was applied to genom...
Rift Valley fever virus (RVFV) is a major zoonotic pathogen causing significant outbreaks in humans and livestock, with no licensed effective vaccines currently available and reverse vaccinology and immunoinformatics approaches were employed to design three multi-epitope mRNA vaccine candidates against RVFV.
E. K. Oladipo, James Akinwumi Ogunniran, Biobele Winner Sokari et al.· Discover Immunity· 0 citations
Dengue virus remains a major global health threat due to its four antigenically diverse serotypes and limited treatment and vaccine options. This study aimed to design and evaluate a rational tetravalent multi-epitope vaccine capable of eliciting broad cross-serotype immune responses against dengue virus. An immunoin...
Theerawat Dobutr, Pemikar Srifa, N. Pinpathomrat· Frontiers in Cellular and In...· 0 citations
Findings indicate that the G1-based multi-epitope vaccine is a potential candidate for further experimental validation and may serve as an effective preventive strategy against OROV infection.
Khadija Khawar, Komal Imran, Muhammad Aamir Sharif et al.· Naunyn-Schmiedeberg's Archiv...· 0 citations
The computational analyses support the proposed multi-epitope construct as a potential vaccine candidate against S. haemolyticus and provide a basis for its further experimental evaluation.
Human metapneumovirus (HMPV) is a primary cause of global respiratory infections yet no approved vaccine currently exists. This study computationally predicts a multi-epitope vaccine candidate using a diverse dataset of 65 HMPV sequences spanning five continents. Following the screening of lead proteins for antigenicit...
N. Alam, Moumita Chakrabarty, Tanmoy Debnath et al.· PLoS ONE· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.